Share Name Share Symbol Market Type Share ISIN Share Description
Mereo Biopharma Group Plc LSE:MPH London Ordinary Share GB00BZ4G2K23 ORD GBP0.003 (REG S)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 26.50 26.00 27.00 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -41.1 -39.0 - 73

Mereo BioPharma Group plc Virtual R&D Day

16/11/2020 12:00pm

RNS Non-Regulatory


Mereo BioPharma Group plc

16 November 2020

Mereo BioPharma to Hold Virtual R&D Day on Tuesday, November 24, 2020

London and Redwood City, Calif., November 16, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) ("Mereo" or "the Company"), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced it will host a virtual R&D day on Tuesday, November 24, to review the Company's key pipeline programs including etigilimab (Anti-TIGIT) for solid tumors and alvelestat for alpha-1 antitrypsin deficiency (AATD) and COVID-19 respiratory disease. The virtual R&D day will feature external experts and will include a more detailed review of the etigilimab development program, including the design and biomarker strategy for the recently initiated Phase 1b/2 basket combination study.

R&D Day Information

Date: Tuesday, November 24, 2020

Time: 12:00 p.m. EST / 5:00 p.m. GMT


-- Timothy Yap, MBBS, PhD, FRCP, Associate Professor, Department of Investigational Cancer Therapeutics, and the Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center

   --    John Strickler, MD, Associate Professor of Medicine, Member of the Duke Cancer Institute 

-- Mark Dransfield, MD, Professor and Interim Director, Division of Pulmonary, Allergy and Critical Care Medicine, The University of Alabama at Birmingham (UAB)

   --    Denise Scots-Knight, Chief Executive Officer 
   --    John Lewicki, Chief Scientific Officer 
   --    Ann Kapoun, SVP of Translational Research and Development 
   --    Alastair MacKinnon, Chief Medical Officer 
   --    Jackie Parkin, Head of the Alvelestat Program 

A live audio webcast of the R&D day can be accessed through the Investors section of the company's website at www.mereobiopharma.com/investors/results-reports-and-presentations . The event is expected to last approximately two hours. An archived replay of the webcast will be made available on the Company's website.

About Mereo BioPharma

Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Mereo's lead oncology product candidate, etigilimab (Anti-TIGIT), has completed a Phase 1a dose escalation clinical trial in patients with advanced solid tumors and has been evaluated in a Phase 1b study in combination with nivolumab in select tumor types. The Company recently announced initiation of a Phase 1b/2 study of etigilimab in combination with an anti-PD-1/PDL-1 in a range of different tumor types. Mereo's rare disease product portfolio consists of setrusumab, which has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta (OI), as well as alvelestat, which is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency (AATD) and in a Phase 1b/2 clinical trial in COVID-19 respiratory disease.

Forward-Looking Statements

This Announcement contains "forward-looking statements." All statements other than statements of historical fact contained in this Announcement are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements usually relate to future events and anticipated revenues, earnings, cash flows or other aspects of our operations or operating results. Forward-looking statements are often identified by the words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," "may," "estimate," "outlook" and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company's current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates.

All of the Company's forward-looking statements involve known and unknown risks and uncertainties some of which are significant or beyond its control and involve assumptions that could cause actual results to differ materially from the Company's historical experience and its present expectations or projections.

These forward-looking statements are subject to risks and uncertainties, including, among other things, those described in the Company's latest Annual Report on Form 20-F, Reports on Form 6-K and other documents filed from time to time by the Company with the United States Securities and Exchange Commission. The Company wishes to caution investors not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

Mereo BioPharma Contacts:

Mereo                                                       +44 (0)333 023 7300 
Denise Scots-Knight, Chief Executive Officer 
N+1 Singer (Nominated Adviser and Broker to Mereo )         +44 (0)20 7496 3081 
Phil Davies 
Will Goode 
Burns McClellan (US Investor Relations Adviser to Mereo )   + 01 212 213 0006 
Lisa Burns 
Lee Roth 
FTI Consulting (UK Public Relations Adviser to Mereo )       +44 (0)20 3727 1000 
Simon Conway 
Ciara Martin 
Investors                                                   investors@ mereo biopharma.com 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

November 16, 2020 07:00 ET (12:00 GMT)

1 Year Mereo Biopharma Chart

1 Year Mereo Biopharma Chart

1 Month Mereo Biopharma Chart

1 Month Mereo Biopharma Chart
ADVFN Advertorial
Your Recent History
Mereo Biop..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210924 21:17:56